Erratum to: Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection: Aristolochic Acid and Risk of HCC (International Journal of Cancer, (2018), 143, 7, (1578-1587), 10.1002/ijc.31544);Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection

International Journal of Cancer

Volumn 143, Issue 7, 2018, Pages 1578-1587

  Chen, Chi Jen ^a,b   Yang, Yao Hsu ^a,c,d   Lin, Meng Hung ^a   Lee, Chuan Pin ^a   Tsan, Yu Tse ^e,f   Lai, Ming Nan ^g   Yang, Hsiao Yu ^c   Ho, Wen Chao ^h   Chen, Pau Chung ^c,i  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^g FENG CHIA UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

aristolochic acid; hepatitis B virus infection; hepatocellular carcinoma; herbal medicine

Indexed keywords

ARISTOLOCHIC ACID;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CHINESE MEDICINE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS B; HERBAL MEDICINE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TAIWAN; ADOLESCENT; CHRONIC HEPATITIS B; COMPLICATION; DRUG EFFECT; HEPATITIS B VIRUS; LIVER TUMOR; PATHOLOGY; PROGNOSIS; RISK FACTOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ARISTOLOCHIC ACIDS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TAIWAN; YOUNG ADULT;

EID: 85046535837     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.32628     Document Type: Erratum

References (43)

1. Cosyns JP, Jadoul M, Squifflet JP, et al. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 1999;33:1011–7
2. Nortier JL, Martinez M-CM, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686–92
3. International Agency for Research on Cancer (IARC). Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr Eval Carcinog Risks Hum 2002;82:69–128
4. International Agency for Research on Cancer (IARC). A review of human carcinogens: pharmaceuticals. IARC Monogr Eval Carcinog Risks Hum 2012;100A:347–61
5. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology 2009;14:227–34
6. Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis 2010;55:507–18
7. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010;102:179–86
8. Yang HY, Wang JD, Lo TC, et al. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J Epidemiol 2009;19:17–23
9. Yang HY, Wang JD, Lo TC, et al. Increased risks of upper tract urothelial carcinoma in male and female Chinese herbalists. J Formos Med Assoc 2011;110:161–8
10. Yang HY, Wang JD, Lo TC, et al. Occupational kidney disease among Chinese herbalists exposed to herbs containing aristolochic acids. Occup Environ Med 2011;68:286–90
11. Yang HY, Wang JD, Lo TC, et al. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. J Urol 2013;189:48–52
12. Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 2012;109:8241–6
13. Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer 2013;133:14–20
14. Hoang ML, Chen CH, Chen PC, et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol Biomarkers Prev 2016; 25:1600–8
15. Mei N, Arlt VM, Phillips DH, et al. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat Res 2006;602:83–91
16. Huang J, Deng Q, Wang Q, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012;44:1117–21
17. Poon SL, Pang ST, McPherson JR, et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013;5:197ra101
18. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 318:2:1129–1133
19. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168–74
20. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73
21. Gökmen MR, Cosyns JP, Arlt VM, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy. Ann Intern Med 2013;158:469–77
22. Hsieh SC, Lin IH, Tseng WL, et al. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med 2008;3:13
23. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. JCO 2012;30:623–30
24. Tsan YT, Lee CH, Ho WC, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol 2013;31:1514–21
25. Regulations regarding Chinese herbal products containing aristolochic acid. Available at https://dep.mohw.gov.tw/docmap/fp-883-5362-108.html [Accessed 2 March 2018]
26. Hsu YH, Tseng HH, Wen KC. Determination of aristolochic acid in Fangchi radix. Ann Rept NLFD Taiwan ROC 1997;15:136–42
27. Deng JS. Quality evaluation of Fang-Ji and analysis of marker constituents. Taichung, Taiwan: Institute of Chinese Pharmaceutical Sciences, China Medical University, 2002. 75–7
28. Chuang MS, Hsu YH, Chang HC, et al. Studies on adulteration and misusage of marketed Akebiae caulisn. Ann Rept NLFD Taiwan ROC 2002;20:104–19
29. Jong TT, Lee MR, Hsiao SS, et al. Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal 2003;33:831–7
30. Hsu YH, Lo CF, Chang HC, et al. Studies on adulteration and misusage of Asari radi in the market. Ann Rept NLFD Taiwan ROC 2003;21:153–67
31. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36
32. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369–80
33. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010;60:207–21
34. Chen FP, Kung YY, Chen YC, et al. Frequency and pattern of Chinese herbal medicine prescriptions for chronic hepatitis in Taiwan. J Ethnopharmacol 2008;117:84–91
35. Sidorenko VS, Yeo JE, Bonala RR, et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 2012; 40:2494–505
36. Rossiello MR, Laconi E, Rao PM, et al. Induction of hepatic nodules in the rat by aristolochic acid. Cancer Lett 1993;71:83–7
37. Ng AWT, Poon SL, Huang MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 2017;9:eaan6446
38. Chen YC, Su YC, Li CY, et al. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int 2015;87:1030–8
39. Chen YC, Su YC, Li CY, et al. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naïve patients with chronic hepatitis B in Taiwan. BMC Nephrol 2015;16:110
40. Wu WC, Chen YT, Hwang CY, et al. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver Int 2013;33:616–23
41. Hwang JC, Weng SF, Weng RH. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study. Jpn J Clin Oncol 2012;42:780–6
42. Loomba R, Yang HI, Su J, et al. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol 2013;177:333–42
43. Wu HC, Wang Q, Yang HI, et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2009;18:846–53